Previous 10 | Next 10 |
2023-09-12 07:21:06 ET More on Avalo Therapeutics Seeking Alpha’s Quant Rating on Avalo Therapeutics Historical earnings data for Avalo Therapeutics Financial information for Avalo Therapeutics Avalo tumbles 89% as mid-stage trial for asthma drug fails...
WAYNE, Pa. and ROCKVILLE, Md. , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D...
WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the H.C. Wainwright 25 th Annual Global Investment Conference being held Septe...
2023-08-18 09:04:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering . That public offering has Athersys selling 10,937,...
2023-08-18 08:49:55 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Farfetch (NYSE: FTCH ) stock is taking a beating on Friday after releasing a disappointing earnings report for the second quarter of 2023. The bad news starts with the l...
2023-08-18 08:29:48 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avalo Therapeutics (NASDAQ: AVTX ) stock is rising higher on Friday despite a lack of news from the biotechnology company. There haven’t been any new press releases o...
2023-08-18 07:27:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting the final day of trading this week with a dive into the biggest pre-market stock movers for Friday! Moving stocks this morning are earnings reports, clinical trial res...
2023-08-03 09:42:01 ET Avalo Therapeutics press release ( NASDAQ: AVTX ): Q2 GAAP EPS of -$0.59 beats by $0.21 . Revenue of $0.64M (-37.9% Y/Y) beats by $0.14M . For further details see: Avalo Therapeutics GAAP EPS of -$0.59 beats by $0.21, revenue of $0....
Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration indicating strong target engagement Disclosed cash of approximately $6.3 million as of June ...
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will participate in the SVB Securities Therapeutics Forum being held Tuesday, July 11th – We...
News, Short Squeeze, Breakout and More Instantly...
Avalo Therapeutics Inc. Company Name:
AVTX Stock Symbol:
NASDAQ Market:
Avalo Therapeutics Inc. Website:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
2024-07-06 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...